Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...
| المؤلفون الرئيسيون: | , , , , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Taylor & Francis Group
2017-09-01
|
| سلاسل: | Human Vaccines & Immunotherapeutics |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://dx.doi.org/10.1080/21645515.2017.1331796 |